U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H14N2.C4H4O4
Molecular Weight 302.3251
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ALTINICLINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CN1CCC[C@H]1C2=CN=CC(=C2)C#C

InChI

InChIKey=BCPPKHPWLRPWBJ-OURKGEEVSA-N
InChI=1S/C12H14N2.C4H4O4/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2;5-3(6)1-2-4(7)8/h1,7-9,12H,4-6H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t12-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C12H14N2
Molecular Weight 186.253
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10812948 https://www.ncbi.nlm.nih.gov/pubmed/18692487

Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.5 nM [Ki]
Conditions
Doses

Doses

DosePopulationAdverse events​
40 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting
Sources:
10 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Other AEs: Lightheadedness, Dizziness...
Other AEs:
Lightheadedness
Dizziness
Sources:
20 mg 2 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Disc. AE: Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (serious, 1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea and vomiting
40 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Dizziness
10 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Lightheadedness
10 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Thrombocytopenia serious, 1 pt
Disc. AE
20 mg 2 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
PubMed

PubMed

TitleDatePubMed
Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.
2000 Sep
Patents

Sample Use Guides

10 mg daily
Route of Administration: Oral
[3H]-DA uptake in rat striatal synaptosomes was conducted as described before: briefly, 100 μl of crude P2 synaptosomal fraction were preincubated in the presence of varying concentrations of test compounds (SIB-1765F) for 10 min before the addition of [3H]-DA final concentration of 10 nM
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:54:26 UTC 2023
Edited
by admin
on Fri Dec 15 15:54:26 UTC 2023
Record UNII
PCL7Q9Q62Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALTINICLINE MALEATE
USAN  
USAN  
Official Name English
(-)-3-ETHYNYL-5-((S)-1-METHYL-2-PYRROLIDINYL)PYRIDINE MALEATE (1:1)
Systematic Name English
ALTINICLINE MALEATE [USAN]
Common Name English
(-)-5-ETHYNYLNICOTINE MALEATE (1:1)
Common Name English
SIB-1508Y
Code English
(S)-3-ETHYNYL-5-(1-METHYL-2-PYRROLIDINYL)PYRIDINE (Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C73579
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL111659
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
PRIMARY
CAS
192231-16-6
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
PRIMARY
PUBCHEM
10968648
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
PRIMARY
NCI_THESAURUS
C90896
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
PRIMARY
MESH
C100989
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
PRIMARY
FDA UNII
PCL7Q9Q62Q
Created by admin on Fri Dec 15 15:54:26 UTC 2023 , Edited by admin on Fri Dec 15 15:54:26 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY